<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683917</url>
  </required_header>
  <id_info>
    <org_study_id>ZPU-202</org_study_id>
    <nct_id>NCT00683917</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids</brief_title>
  <official_title>A Multi-center, Active Controlled, Pharmacokinetic, Safety and Efficacy Study of Proellex in Pre-Menopausal Women With Symptomatic Uterine Fibroids to Assess Persistence of Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the pharmacokinetics (PK) of 25 mg and 50 mg Proellex®
      administered once daily (QD) over a 4-month period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Repros stopped the study for safety and FDA put the study on hold for safety.
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure is the PK Characteristics of 25 mg and 50 mg Proellex.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Proellex 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proellex 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proellex 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proellex 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lupron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lupron Depot</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 25 mg</intervention_name>
    <description>Proellex 25 mg, 1 capsule daily for 4 months</description>
    <arm_group_label>Proellex 25 mg</arm_group_label>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 50 mg</intervention_name>
    <description>Proellex 50 mg, 2 capsules daily for 4 months</description>
    <arm_group_label>Proellex 50 mg</arm_group_label>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lupron Depot</intervention_name>
    <description>Lupron 3.75 mg monthly intramuscular injections for 4 months</description>
    <arm_group_label>Lupron</arm_group_label>
    <other_name>Leuprolide acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects between the ages of 18 and 45 years with body mass index (BMI) between
             18 and 35 mg/kg2 inclusive

          -  Surgical interventions for uterine fibroids (e.g., hysterectomy, myomectomy, or
             uterine arterial embolization) must not be planned or anticipated during the study

          -  Subject must have the following uterine fibroid-associated symptom: history of
             excessive menstrual bleeding

          -  Regular or steady menstrual cycle lasting from 24 to 36 days

          -  Willing to comply with all study procedures including the endometrial biopsies and PK
             blood draws for all visits including follow-up visits

          -  Subject must agree to use a medically acceptable and effective non-hormonal, double
             barrier birth control method throughout the study and for 30 days following the end of
             the study or discontinuation of study drug

        Exclusion Criteria:

          -  Documented endometriosis or active pelvic inflammatory disease

          -  History of alcohol and/or drug abuse

          -  Any history or diagnosis of gynecological cancer or cervical dysplasia

          -  Use of an IUD

          -  Use of prohibited concomitant medications:

               -  Use of Depo-Provera must cease 10 months prior to first dose of study drug

               -  Use of GnRH agonists (e.g., Lupron®) must cease 4 months prior to first dose of
                  study drug and Lupton® Depot 8 months prior to the first visit

          -  Known active infection with HIV; Hepatitis A, B or C; gonorrhea; or chlamydia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre vanAs, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Physician Care Clinical Research</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances in Health, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Cientificos y Clinicos Pharma, S.A. de C.V. (CECYC-Pharma)</name>
      <address>
        <city>Mexico City</city>
        <state>Federal District</state>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <results_first_submitted>June 25, 2014</results_first_submitted>
  <results_first_submitted_qc>August 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2014</results_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine fibroids</keyword>
  <keyword>Fibroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Proellex All Groups</title>
          <description>Proellex 25 mg: Proellex 50 mg, placebo, 1 capsule daily for 4 months Study prematurely terminated, no further data available</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study prematurely terminated</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study prematurely terminated</population>
      <group_list>
        <group group_id="B1">
          <title>Proellex 25 mg</title>
          <description>Proellex 25 mg: Proellex 25 mg, 1 capsule daily for 4 months</description>
        </group>
        <group group_id="B2">
          <title>Proellex 50 mg</title>
          <description>Proellex 50 mg: Proellex 50 mg, 2 capsules daily for 4 months</description>
        </group>
        <group group_id="B3">
          <title>Lupron</title>
          <description>Lupron Depot: Lupron 3.75 mg monthly intramuscular injections for 4 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure is the PK Characteristics of 25 mg and 50 mg Proellex.</title>
        <time_frame>4 months</time_frame>
        <population>Study prematurely terminated</population>
        <group_list>
          <group group_id="O1">
            <title>Proellex 25 mg</title>
            <description>Proellex 25 mg: Proellex 25 mg, 1 capsule daily for 4 months</description>
          </group>
          <group group_id="O2">
            <title>Proellex 50 mg</title>
            <description>Proellex 50 mg: Proellex 50 mg, 2 capsules daily for 4 months</description>
          </group>
          <group group_id="O3">
            <title>Lupron</title>
            <description>Lupron Depot: Lupron 3.75 mg monthly intramuscular injections for 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Measure is the PK Characteristics of 25 mg and 50 mg Proellex.</title>
          <population>Study prematurely terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse event data is available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Proellex 25 mg</title>
          <description>Proellex 25 mg: Proellex 25 mg, 1 capsule daily for 4 months</description>
        </group>
        <group group_id="E2">
          <title>Proellex 50 mg</title>
          <description>Proellex 50 mg: Proellex 50 mg, 2 capsules daily for 4 months</description>
        </group>
        <group group_id="E3">
          <title>Lupron</title>
          <description>Lupron Depot: Lupron 3.75 mg monthly intramuscular injections for 4 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jennifer Wike</name_or_title>
      <organization>Repros Therapeutics Inc.</organization>
      <phone>2817193402</phone>
      <email>jwike@reprosrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

